During the past decade, Hospital de la Ribera conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 12 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 9 clinical trials were completed. i.e. 39.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital de la Ribera" #1 sponsor was "Eli Lilly and Company" with 7 trials, followed by "Hospital de la Ribera" with 5 trials sponsored, "Spanish Breast Cancer Research Group" with 4 trials sponsored, "Celgene" with 3 trials sponsored and "PETHEMA Foundation" with 3 trials sponsored. Other sponsors include 31 different institutions and companies that sponsored additional 32 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital de la Ribera" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Hoffmann-La Roche" with 3 trials as a collaborator, "Hospital de la Ribera" with 3 trials as a collaborator, "University of Valencia" with 3 trials as a collaborator and "Bristol-Myers Squibb" with 2 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Hospital de la Ribera" are "Breast Cancer" (7 trials), "Diabetes Mellitus, Type 2" (4 trials), "Acromegaly" (3 trials), "Multiple Myeloma" (3 trials) and "Type 2 Diabetes" (3 trials). Many other conditions were trialed in "Hospital de la Ribera" in a lesser frequency.

Most popular intervention types in "Hospital de la Ribera" are "Drug" (32 trials), "Other" (13 trials), "Device" (7 trials), "Procedure" (5 trials) and "Behavioral" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Tirzepatide" (4 trials), "Cyclophosphamide" (3 trials), "CAM2029 (octreotide subcutaneous depot)" (2 trials) and "Docetaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hospital de la Ribera" are 49 trials for "All" genders and 9 trials for "Female" genders.

Currently, there are NaN active trials in "Hospital de la Ribera". undefined are not yet recruiting, 12 are recruiting, 5 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 32 completed trials in Hospital de la Ribera, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital de la Ribera, 2 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 13 trials that are defined as “Not Applicable".